VistaGen Therapeutics (NASDAQ:VTGN) Announces Earnings Results, Beats Expectations By $0.14 EPS

VistaGen Therapeutics (NASDAQ:VTGN) issued its quarterly earnings results on Friday. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.14, FiscalAI reports. The firm had revenue of $0.14 million during the quarter, compared to analyst estimates of $0.50 million. VistaGen Therapeutics had a negative net margin of 2,702.64% and a negative return on equity of 152.59%.

VistaGen Therapeutics Trading Up 1.0%

VTGN traded up $0.00 during trading on Friday, hitting $0.18. 420,444 shares of the company’s stock were exchanged, compared to its average volume of 753,991. VistaGen Therapeutics has a 1 year low of $0.16 and a 1 year high of $5.14. The stock has a 50 day moving average price of $0.22 and a 200 day moving average price of $0.42. The firm has a market cap of $8.01 million, a P/E ratio of -0.11 and a beta of 0.49.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of VistaGen Therapeutics in a report on Monday, August 31st. Four equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce” and an average target price of $0.95.

VistaGen Therapeutics Company Profile

Vistagen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company developing therapies for central nervous system and neuropsychiatric disorders. The company focuses on intranasal treatments designed to act rapidly and address conditions for which patients may need alternatives to conventional systemic medicines. Vistagen’s lead investigational product is fasedienol, also known as PH94B, a nasal spray being studied as a potential treatment for social anxiety disorder. The company’s pipeline has also included PH80, an intranasal therapy investigated for migraine and other neurological conditions, and PH10, an intranasal neuroactive compound studied for depressive disorders.